EUVIMEDEUVIMED entdecken
Crossref

High proportion of wild-type gastrointestinal stromal tumor in a cohort of Chilean patients screened by KIT and PDGFRA exome profiling

Matías Muñoz-Medel, Miguel Córdova-Delgado, Ignacio N. Retamal, Fabián Villalobos, Rosemarie Mellado, Piga Fernández, Patricio Manque, Alejandro Berkovits, Juvenal A. Ríos, Benjamín García-Bloj, María Paz Rodríguez, Marcelo Garrido

Gastrointestinal Stromal Tumor · 2022

DOI: 10.21037/gist-21-19 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastrointestinal Stromal Tumor, 2022. Verfasst von Matías Muñoz-Medel und 11 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

About 80–90% of gastrointestinal stromal tumor (GIST) patients harbor KIT proto-oncogene (KIT) and/or platelet-derived growth factor receptor alpha (PDGFRA) gain-of-function mutations. The KIT gene also encodes a tyrosine kinase receptor; therefore, KIT/PDGFRA alterations not only serve as hallmarks, but also as potential therapeutic targets. Previous reports have demonstrated that differences in the KIT/PDGFRA mutation rates are generally attributed to ethnic and/or technical factors. Herein, we report a molecular profiling of KIT/PDGFRA in a Latin American cohort of GIST patients.

Methods

In this observational study, DNA samples were obtained from paraffin blocks in 42 GIST patients. We performed KIT/PDGFRA molecular profiling by Sanger sequencing. Patients’ clinical characteristics were obtained from their medical records. A single case was further analyzed with next-generation sequencing (NGS).

Results

Patients were predominantly females (n=22; 52.4%). Median age at diagnosis was 53 years old. As expected, the stomach was the most frequent primary location (47.6%), and 38.1% of cases were metastatic. We detected KIT and PDGFRA alterations in 64.3% and 4.8% of patients, respectively. Within this subset (n=29), 82.8% had exon-11 KIT mutations, and 6.9% had exon 18 PDGFRA mutations. As predicted, KIT and PDGFRA mutations were mutually exclusive, and 31% (n=13) were wild-type KIT/PDGFRA. These results could be attributed to ethnic and methodological differences. Therefore, we presented a case of a metastatic patient analyzed by NGS to illustrate the clinical utility of an alternative screening strategy to Sanger sequencing.

Conclusions

There were a high proportion of wild-type GISTs in this cohort. This could be attributed to technical/methodological and/or ethnic/genetic differences. Our findings also encourage the use of alternative techniques, such as NGS for KIT/PDGFRA screenings, particularly in the case of advanced-stage patients.

Zitieren

APA

Muñoz-Medel, M., Córdova-Delgado, M., Retamal, I. N., Villalobos, F., Mellado, R., Fernández, P., Manque, P., Berkovits, A., Ríos, J. A., García-Bloj, B., Rodríguez, M. P., & Garrido, M. (2022). High proportion of wild-type gastrointestinal stromal tumor in a cohort of Chilean patients screened by KIT and PDGFRA exome profiling. Gastrointestinal Stromal Tumor. https://doi.org/10.21037/gist-21-19

Vancouver

Muñoz-Medel M, Córdova-Delgado M, Retamal IN, Villalobos F, Mellado R, Fernández P, et al. High proportion of wild-type gastrointestinal stromal tumor in a cohort of Chilean patients screened by KIT and PDGFRA exome profiling. Gastrointestinal Stromal Tumor. 2022. doi:10.21037/gist-21-19

BibTeX
@article{MuozMedel2022,
  author = {Muñoz-Medel, Matías and Córdova-Delgado, Miguel and Retamal, Ignacio N. and Villalobos, Fabián and Mellado, Rosemarie and Fernández, Piga and Manque, Patricio and Berkovits, Alejandro and Ríos, Juvenal A. and García-Bloj, Benjamín and Rodríguez, María Paz and Garrido, Marcelo},
  title = {High proportion of wild-type gastrointestinal stromal tumor in a cohort of Chilean patients screened by KIT and PDGFRA exome profiling},
  journal = {Gastrointestinal Stromal Tumor},
  year = {2022},
  doi = {10.21037/gist-21-19}
}
Kostenlos starten →